Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $23.00 at Piper Sandler

Inozyme Pharma (NASDAQ:INZY) had its target price cut by Piper Sandler from $30.00 to $23.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other analysts have also recently weighed in on INZY. Needham & Company LLC dropped their price objective on shares of Inozyme Pharma from $23.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday. Wells Fargo & Company dropped their price target on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Inozyme Pharma in a research report on Tuesday. Raymond James assumed coverage on Inozyme Pharma in a report on Thursday, December 12th. They issued an “outperform” rating and a $26.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $7.00 target price (down previously from $12.00) on shares of Inozyme Pharma in a research note on Monday. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Inozyme Pharma has an average rating of “Buy” and a consensus price target of $14.56.

Inozyme Pharma Trading Down 7.4 %

NASDAQ INZY opened at $1.00 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. Inozyme Pharma has a one year low of $0.98 and a one year high of $7.80. The company has a 50-day simple moving average of $1.48 and a 200-day simple moving average of $3.26. The firm has a market capitalization of $64.22 million, a PE ratio of -0.64 and a beta of 1.32.

Hedge Funds Weigh In On Inozyme Pharma

Large investors have recently bought and sold shares of the stock. Harvest Investment Services LLC bought a new position in Inozyme Pharma during the fourth quarter valued at about $31,000. Graham Capital Management L.P. acquired a new stake in shares of Inozyme Pharma during the 4th quarter worth approximately $33,000. Virtu Financial LLC bought a new stake in shares of Inozyme Pharma during the third quarter valued at approximately $64,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Inozyme Pharma in the fourth quarter valued at $38,000. Finally, ProShare Advisors LLC acquired a new position in shares of Inozyme Pharma in the fourth quarter valued at $49,000. 88.30% of the stock is currently owned by institutional investors and hedge funds.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.